Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

NCT00059904 | Completed Phase 2

• 3 other identifiers: CHIR-IL2005-A01MSKCC-03004CDR0000298986
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining rituximab with interleukin-2 may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with interleukin-2 in treating patients who have relapsed or refractory intermediate- or high-grade non-Hodgkin's lymphoma.

Conditions

Lymphoma

Keywords

recurrent adult diffuse large cell lymphoma; recurrent adult diffuse mixed cell lymphoma; recurrent adult immunoblastic large cell lymphoma

Interventions

aldesleukin BIOLOGICAL

rituximab BIOLOGICAL

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Diagnosis of intermediate- or high-grade non-Hodgkin's lymphoma according to the Working Formulation, including the following subtypes: * Diffuse large cell lymphoma * Diffuse mixed cell lymphoma * Immunoblastic large cell lymphoma * CD20+ disease * Measurable progressive or refractory disease * No primary CNS lymphoma or lymphomatous meningitis NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology. PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * Not specified Hematopoietic * Lymphocyte count less than 20,000/mm\^3 * Absolute neutrophil count at least 1,000/mm\^3 * Platelet count at least 75,000/mm\^3 * Hemoglobin at least 9.5 g/dL Hepatic * SGOT and SGPT no greater than 1.5 times upper limit of normal * Bilirubin normal * No liver disease * Hepatitis C-seropositive patients are allowed provided they have no active disease, as demonstrated by any of the following: * Undetectable hepatitis C viral loads * Biopsy showing no active disease * Normal transaminases on at least 3 different occasions within the past year Renal * Creatinine normal Cardiovascular * No clinically significant cardiac dysfunction * No myocardial infarction within the past 6 months * No heart failure within the past 6 months Pulmonary * No clinically significant pulmonary dysfunction * Patients with prior radiotherapy to the lung or autologous transplantation must have FEV greater than 50% and DLCO greater than 50% within 8 weeks before study treatment Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative * No significant infections within the past 2 weeks (including pneumonia or bronchitis) * No history of autoimmune disease * No prior or concurrent malignancy except inactive nonmelanoma skin cancer, carcinoma in situ of the cervix, or other solid tumor curatively treated with no evidence of recurrence within the past 2 years * No symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism * No prior type 1 hypersensitivity or anaphylactic reactions to murine products, rituximab, or radioimmunoconjugated anti-CD20 antibody infusion PRIOR CONCURRENT THERAPY: Biologic therapy * At least 3 months since prior autologous bone marrow transplantation * No prior allogeneic bone marrow transplantation * No prior interleukin-2 * No prior interferon (alfa, beta, or gamma) * No concurrent basiliximab, daclizumab, or monoclonal antibody OKT3 Chemotherapy * More than 30 days since prior chemotherapy * No concurrent anticancer chemotherapy Endocrine therapy * More than 2 weeks since prior systemic steroids * No concurrent systemic corticosteroids Radiotherapy * More than 30 days since prior radiotherapy * No concurrent radiotherapy Surgery * More than 30 days since prior major surgery Other * More than 30 days since other prior investigational drugs * More than 30 days since prior immunosuppressive medications * No concurrent immunosuppressive medications including the following: * Cyclosporine * Mycophenolate mofetil * Tacrolimus * Sirolimus

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead
• National Cancer Institute (NCI): collaborator

Study Sites (1)

Memorial Sloan-Kettering Cancer Center

New York, New York, 10021, United States

Location

MeSH Terms

Conditions

Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Immunoblastic

Interventions

aldesleukin; Rituximab

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Lymphoma, B-Cell

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Murine-Derived; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• Tarun Kewalramani, MD

  Memorial Sloan Kettering Cancer Center

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Masking: NONE
• Purpose: TREATMENT
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: May 6, 2003
• First Posted: May 7, 2003
• Study Start: January 1, 2003
• Study Completion: June 1, 2004
• Last Updated: July 18, 2013

Record last verified: 2004-07

Locations

US (1)